Get Support

Learn Mode

IQV - IQVIA Holdings Inc

38

$173.26

$0.86 (0.499%)

At market close

$173.27

$0.01 (0.006%)

After Hours 4/2/26, 8:05 PM

3.63/5

General

Scores

Financials & KPIs

Dividends

Analyst

Insider

IQV

Valuation Score

View as %

Stock Unlock

1D

1W

1M

YTD

1Y

3Y

5Y

Max

Stock Profile

Market Cap

$29.40B

Industry

Life Sciences Tools & Services

EPS (TTM)

$7.92

P/E (TTM)

21.62

Div & Yield

--

FCF Payout Ratio

--

P/S (TTM)

1.80

P/B

4.52

Diluted Shares

171.70M

Ex-Dividend

--

Next Earnings

05-04

Forward P/E

13.19

Payout Ratio

--

P/FCF (TTM)

14.34

FCF Yield

6.98%

Earnings Yield

4.63%

52 Week Range

Score Card

Explore Scores Tab

3.63

Good

IQVIA Holdings Inc has grown revenue at 5.87% over the past year, which suggests sales are increasing. Also, it has seen its diluted average shares outstanding decrease by -4.98% over the past year, which suggests the company is buying back shares.

Valuation Model

Key Score

4.00

Good

Management

1.00

Very Bad

Growth

2.00

Bad

Profitability

1.00

Very Bad

Fin. Health

1.00

Very Bad

Dividends

--

--

Analyst

1.00

Very Bad

Insider Transactions

Explore Insider Tab

Buy

Sell

Market News

Page 1 of 21

Filter Form Types

Form SCHEDULE 13G/A

Unknown Form Type

Filed on 2026-03-27 09:54:26

Form ARS

Unknown Form Type

Filed on 2026-02-27 16:55:20

Form DEFA14A

Additional definitive proxy soliciting materials

Filed on 2026-02-27 16:54:04

Form DEF 14A

Also known as a 'definitive proxy statement', is a required filing when a shareholder vote is required

Filed on 2026-02-27 16:52:32

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 17:01:48

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-17 17:01:10

Form 10-K

Annual financials report pursuant to Section 13 or 15(d)

Filed on 2026-02-17 07:46:53

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-11 17:11:44

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-11 17:11:19

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-11 17:10:52

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-11 17:10:29

Form 4

Statement of changes in beneficial ownership of securities - general instructions

Filed on 2026-02-11 17:10:04

Page 1 of 21

Financials

Explore Financials Tab

Revenue

Earnings

Free Cash Flow

Price Targets

Go to Analyst Tab

These are one year price targets for: 2027-03-25

High:

$301.35

73.9%

Avg:

$243.06

40.3%

Low:

$202.00

16.6%

(% change is relative to the current stock price: $173.26)

Analyst Recommendations

Go to Analyst Tab

4.13

Good

33%

Strong Buy (10)

47%

Buy (14)

20%

Hold (6)

0%

Sell (0)

0%

Strong Sell (0)

About

Website
https://ir.iqvia.com/
Address
2400 Ellis Road, Durham NORTH CAROLINA, US
SEC Reports
https://sec.gov/edgar/browse/?CIK=1478242

IQVIA Holdings, Inc. engages in the provision of analytics, technology solutions, and clinical research services to the life sciences industry. The company is headquartered in Durham, North Carolina and currently employs 93,000 full-time employees. The company went IPO on 2013-05-09. Its segments include Technology & Analytics Solutions, Research & Development Solutions and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment provides mission-critical information, technology solutions and real-world insights and services to the Company’s life science clients. The Research & Development Solutions segment primarily serves biopharmaceutical customers, and provides outsourced clinical research and clinical trial-related services. The Contract Sales & Medical Solutions segment provides healthcare provider (including contract sales) and patient engagement services to both biopharmaceutical customers and the broader healthcare market. The company offers a set of strategic and implementation consulting services, including advanced analytics and commercial processes outsourcing services.

IPO Date

2013-05-09

Industry

Life Sciences Tools & Services

Total Employees

88,000

Exchange

New York Stock Exchange, Inc.

Reporting Currency

USD

GICS

Life Sciences Tools & Services

GICS Sub

Life Sciences Tools & Services

GICS Sector

Health Care

GICS Group

Pharmaceuticals, Biotechnology & Life Sciences